• Biopharma provider purchases property in Science Park III of Ulm • Laboratory and office facility to be constructed on the site by 2019 Göttingen/Laupheim, December 14, 2016 – Sartorius Stedim Cellca based near Ulm in southern Germany, continues on the growth track. At the end of November, the company in its eleventh year since More
New services to enable U.S. biopharmaceutical companies to accelerate development of biosimilar. Goettingen, Germany | Boston, MA, USA – November 10, 2016: Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, opened a new bioanalytical and biosafety testing laboratory yesterday in the major biotech hub of Boston, Massachusetts. This dedicated bioanalytical laboratory More
Read our biosafety testing services brochure.
Collaborative poster with DiscoverX on the development and evaluation of novel bioassay for Denosumab activity.
Improve speed to clinic and mitigate risk with appropriate analytical analysis View webinar here.
View our latest poster on orthogonal analytics for biosimilars
Reduce risk of biosimilar development with an orthogonal approach to physicochemical and bioanalytical methods
Read our latest white paper of using orthogonal methods during biosimilar development.
Read our article on the advances in biosimilar development. Read the full magazine here. *This article is taken from European Biopharmaceutical Review October 2016, pages 12-17. © Samedan Ltd
Our Senior Technical Marketing Manager, Brian Wendelburg recently wrote an article for Laboratory news discussing how successful biosimilar mAbs have been and the challenges that remain. To read the full article, click here.
Read our cell line development brochure.